NOVO.B.DK

437.75

+1.74%↑

GMAB.DK

1,311.5

-0.68%↓

HLUNB.DK

35.52

-1.22%↓

ZEAL.DK

358.8

+1.61%↑

AMBUB.DK

100

-0.2%↓

NOVO.B.DK

437.75

+1.74%↑

GMAB.DK

1,311.5

-0.68%↓

HLUNB.DK

35.52

-1.22%↓

ZEAL.DK

358.8

+1.61%↑

AMBUB.DK

100

-0.2%↓

NOVO.B.DK

437.75

+1.74%↑

GMAB.DK

1,311.5

-0.68%↓

HLUNB.DK

35.52

-1.22%↓

ZEAL.DK

358.8

+1.61%↑

AMBUB.DK

100

-0.2%↓

NOVO.B.DK

437.75

+1.74%↑

GMAB.DK

1,311.5

-0.68%↓

HLUNB.DK

35.52

-1.22%↓

ZEAL.DK

358.8

+1.61%↑

AMBUB.DK

100

-0.2%↓

NOVO.B.DK

437.75

+1.74%↑

GMAB.DK

1,311.5

-0.68%↓

HLUNB.DK

35.52

-1.22%↓

ZEAL.DK

358.8

+1.61%↑

AMBUB.DK

100

-0.2%↓

Search

Coloplast A-S (Class B)

Atidarymo kaina

598.6 -1.06

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

597.8

Max

610

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-132M

912M

Pardavimai

-96M

6.9B

P/E

Sektoriaus vid.

30.208

50.291

Pelnas, tenkantis vienai akcijai

4.34

Dividendų pajamingumas

3.61

Pelno marža

13.16

Darbuotojai

16,741

EBITDA

-42M

2.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+11.86% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.61%

2.40%

Kitas uždarbis

2025-08-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-19B

138B

Ankstesnė atidarymo kaina

599.66

Ankstesnė uždarymo kaina

598.6

Coloplast A-S (Class B) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-26 23:49; UTC

Uždarbis

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

2025-06-26 22:19; UTC

Įsigijimai, susijungimai, perėmimai

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

2025-06-26 21:30; UTC

Uždarbis

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Uždarbis

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

2025-06-26 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

2025-06-26 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

2025-06-26 23:34; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

2025-06-26 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers Will No Longer Receive Earnings From BWP Management

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

2025-06-26 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

2025-06-26 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

2025-06-26 23:19; UTC

Įsigijimai, susijungimai, perėmimai

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

2025-06-26 22:06; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:15; UTC

Uždarbis

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

2025-06-26 21:07; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

2025-06-26 21:06; UTC

Rinkos pokalbiai

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 20:52; UTC

Uždarbis

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

2025-06-26 20:51; UTC

Uždarbis

Correct: Nike 4Q Net $211M, Not $200M >NKE

2025-06-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-26 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Coloplast A-S (Class B) Prognozė

Kainos tikslas

By TipRanks

11.86% į viršų

12 mėnesių prognozė

Vidutinis 901.38 DKK  11.86%

Aukščiausias 1,056 DKK

Žemiausias 720 DKK

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Coloplast A-S (Class B) kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

8 ratings

2

Pirkti

4

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.